Medical News

RSS

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

19 Feb 2014

Long-term care insurance costs up after insurer miscalculations

Prices to buy long-term care insurance have risen during the last few years after insurance company mistakes came to light.

19 Feb 2014

Matching the right tumor with the right drug

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

19 Feb 2014

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

In Uganda the prescription of three antiretroviral (ARV) drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.

18 Feb 2014

A non-invasive method developed to fight heart disease

Clemson University researchers have developed nanoparticles that can deliver drugs targeting damaged arteries, a non-invasive method to fight heart disease.

18 Feb 2014

Democratic Party strategists formulate health law plan for campaign season

The party is seeking to neutralize GOP candidates' ability to use the health overhaul to their advantage.

18 Feb 2014

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Tel Aviv University researchers won two out of three prestigious melanoma research awards granted this year by The Melanoma Research Alliance and The Saban Family Foundation. The Team Science Awards are the centerpiece of the MRA research fund, which seeks to promote transformational melanoma research for swift clinical implementation.

18 Feb 2014

Discovery could lead to improved early detection, prevention strategies for sudden cardiac death

UC Irvine researchers have found a specific genetic flaw that is connected to sudden death due to heart arrhythmia - a leading cause of mortality for adults around the world.

18 Feb 2014

Scientists develop mathematical method for classifying forms of glioblastoma

Scientists at The Wistar Institute have developed a mathematical method for classifying forms of glioblastoma, an aggressive and deadly type of brain cancer, through variations in the way these tumor cells "read" genes. Their system was capable of predicting the subclasses of glioblastoma tumors with 92 percent accuracy. With further testing, this system could enable physicians to accurately predict which forms of therapy would benefit their patients the most.

18 Feb 2014

Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced the launch of Hereditary Colorectal Cancer DNA Insight, the company's premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient's risk of developing certain types of cancer.

18 Feb 2014

DUKAL, Vancive Medical Technologies ink distribution agreement for BeneHold Absorbent Wound Dressings

Vancive Medical Technologies and DUKAL Corporation today announced an agreement for the distribution of the Vancive BeneHold Absorbent Wound Dressing range in the United States and Canada. The BeneHold range includes the Thin Absorbent Wound Dressing, the Standard Hydrocolloid Dressing and the Bordered Hydrocolloid Dressing with Odor Control.

18 Feb 2014

BioFire Diagnostics submits FilmArray GI Panel to FDA for 510(k) clearance

BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration for 510(k) clearance. The comprehensive FilmArray GI Panel tests for over 20 common bacteria, viruses and parasites that cause infectious diarrhea.

18 Feb 2014

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Viamet Pharmaceuticals Inc. today reported positive interim results from an ongoing Phase 2 study of VT-1161, the Company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC).

18 Feb 2014

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

Update Pharma Inc. today announced that the FDA has approved Orphan Drug Status for the use of UPI-928 for the treatment of Acute Myeloid Leukemia (AML).

18 Feb 2014

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.

18 Feb 2014

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

Buckhead Dental Partners' Jeff Ballard selected as one of Atlanta's Five Star Dentists for 2014

Five Star Professional is pleased to announce Jeff Ballard, Buckhead Dental Partners, has been chosen as one of Atlanta's Five Star Dentists for 2014.

18 Feb 2014

HealthStream fourth quarter 2013 revenues up 33%

HealthStream, Inc., a leading provider of workforce development (which we have previously referred to as "learning and talent management") and research / patient experience solutions for the healthcare industry, announced today results for the fourth quarter and full year ended December 31, 2013.

18 Feb 2014

Validic Labs launched to bridge the gap between healthcare companies and mHealth data producers

Validic, pioneer of the first truly inclusive mobile health marketplace, announced today the latest innovation to its data-leveraging platform. Validic has launched Validic Labs in an effort to further bridge the gap between mHealth data producers and healthcare companies. Validic Labs facilitates a simple connection between the app and device developers and the healthcare system in an effort to foster faster, more productive healthcare innovation on both sides.

18 Feb 2014

Verbal memory may signal disease course in first-episode psychosis

Verbal memory appears to be a predictor of clinical remission in patients with first-episode psychosis, according to Canadian researchers writing in Schizophrenia Research.

18 Feb 2014

Medical News

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

Long-term care insurance costs up after insurer miscalculations

Matching the right tumor with the right drug

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

A non-invasive method developed to fight heart disease

Democratic Party strategists formulate health law plan for campaign season

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Discovery could lead to improved early detection, prevention strategies for sudden cardiac death

Scientists develop mathematical method for classifying forms of glioblastoma

Pathway Genomics announces launch of Hereditary Colorectal Cancer DNA Insight genetic test

DUKAL, Vancive Medical Technologies ink distribution agreement for BeneHold Absorbent Wound Dressings

BioFire Diagnostics submits FilmArray GI Panel to FDA for 510(k) clearance

Viamet announces positive interim results from VT-1161 Phase 2 study in patients with AVVC

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Buckhead Dental Partners' Jeff Ballard selected as one of Atlanta's Five Star Dentists for 2014

HealthStream fourth quarter 2013 revenues up 33%

Validic Labs launched to bridge the gap between healthcare companies and mHealth data producers

Verbal memory may signal disease course in first-episode psychosis

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Latest News